S.M. Keller
Merck & Co., Inc., Rahway, NJ, USA (United States) · 32 works · 808 citations · h-index 11
Top works
- LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)
- Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma.
- The effect of aspartame as part of a multidisciplinary weight-control program on short- and long-term control of body weight
- The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer
- Chronic post thoracotomy pain.
- p53 and disease progression in patients with non-small cell lung cancer
- 930MO PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091
- Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stages II and IIIa non-small cell lung cancer: An intergroup trial (E3590)
- VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study
- Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC).
- 18F-fluorodeoxyglucose positron emission tomography: False-positive lung scan
- E1201: An Eastern Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/RT or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged adenocarcinoma of the esophagus
- Combined MEK and mTOR suppression is synergistic in human NSCLC and is mediated via inhibition of protein translation
- Survival outcome of E1201: An Eastern Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/radiotherapy (RT) or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged esophageal adenocarcinoma
- Overcoming the barriers to treatment of rare cancer patients in the era of precision oncology: A call to action
- 120MO Adjuvant pembrolizumab versus placebo for early-stage NSCLC after resection and optional chemotherapy: Updated results from PEARLS/KEYNOTE-091
- 143
- LBA67 Perioperative pembrolizumab in early-stage non-small- cell lung cancer (NSCLC): 5-year follow-up from KEYNOTE- 671
- Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small cell lung cancer: Results from an ECOG prospective randomized trial of postoperative adjuvant therapy (E3590, INT0015)
- Outcome of E1201: An Eastern Cooperative Oncology Group (ECOG) Randomized Phase II Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/RT or Irinotecan/Cisplatin/RT in Endoscopy with Ultrasound (EUS) Staged Esophageal Adenocarcinoma